Shares of Alumis Inc. (NASDAQ:ALMS – Get Free Report) have been given an average recommendation of “Buy” by the six research firms that are currently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $28.00.
A number of equities research analysts have weighed in on the stock. Morgan Stanley initiated coverage on shares of Alumis in a research note on Tuesday, July 23rd. They set an “overweight” rating and a $36.00 target price for the company. HC Wainwright began coverage on shares of Alumis in a research report on Thursday, October 17th. They issued a “buy” rating and a $30.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a report on Monday, August 19th. Leerink Partners started coverage on shares of Alumis in a report on Tuesday, July 23rd. They set an “outperform” rating and a $29.00 price target on the stock. Finally, Guggenheim began coverage on Alumis in a report on Tuesday, July 23rd. They set a “buy” rating and a $32.00 price target on the stock.
Read Our Latest Stock Analysis on ALMS
Institutional Inflows and Outflows
Alumis Stock Performance
Alumis stock opened at $12.04 on Thursday. Alumis has a one year low of $9.54 and a one year high of $13.53. The firm’s fifty day simple moving average is $11.65.
Alumis (NASDAQ:ALMS – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($23.10) EPS for the quarter, missing analysts’ consensus estimates of ($1.57) by ($21.53). As a group, equities analysts anticipate that Alumis will post -6.86 EPS for the current fiscal year.
About Alumis
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Stories
- Five stocks we like better than Alumis
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How to Invest in Biotech Stocks
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Election Stocks: How Elections Affect the Stock Market
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.